Cargando…
The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature
The efficacy and safety of the combination of endocrine therapy (ET) and CDK4/6 inhibitors for patients with hormone receptor (HR)-positive HER2-negative metastatic breast cancer (BC) presenting with visceral crisis or life-threatening conditions represent a challenge for daily clinical practice. In...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529000/ https://www.ncbi.nlm.nih.gov/pubmed/34692469 http://dx.doi.org/10.3389/fonc.2021.651723 |
_version_ | 1784586370881159168 |
---|---|
author | Garufi, Giovanna Carbognin, Luisa Orlandi, Armando Palazzo, Antonella Tortora, Giampaolo Bria, Emilio |
author_facet | Garufi, Giovanna Carbognin, Luisa Orlandi, Armando Palazzo, Antonella Tortora, Giampaolo Bria, Emilio |
author_sort | Garufi, Giovanna |
collection | PubMed |
description | The efficacy and safety of the combination of endocrine therapy (ET) and CDK4/6 inhibitors for patients with hormone receptor (HR)-positive HER2-negative metastatic breast cancer (BC) presenting with visceral crisis or life-threatening conditions represent a challenge for daily clinical practice. Indeed, the peculiarity of this clinical presentation (signs and symptoms of rapidly progressive disease) does not allow to include such patients in a trial aiming for drug approval. On the basis of the scientific evidence available so far, chemotherapy represents the standard of care according to guidelines, on the basis of the more rapid activity in comparison with ET alone. Besides, the combination of ET and CDK4/6 inhibitors have demonstrated in clinical trials to have clinically impactful activity in a short time, thus suggesting a potential role in advanced tumors that require rapid response. Herein, we report the clinical history of a young woman with HR-positive HER2-negative metastatic BC and a pancytopenia due to carcinomatosis of the bone marrow receiving letrozole and leuprorelin plus the CDK4/6 inhibitor palbociclib, who significantly derived clinical benefit from treatment. Considering that these peculiar cases are excluded from clinical trials, the estimation of the magnitude of the benefit of the newer ET combination may potentially represent a practical question for large case series and real-world studies. |
format | Online Article Text |
id | pubmed-8529000 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85290002021-10-22 The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature Garufi, Giovanna Carbognin, Luisa Orlandi, Armando Palazzo, Antonella Tortora, Giampaolo Bria, Emilio Front Oncol Oncology The efficacy and safety of the combination of endocrine therapy (ET) and CDK4/6 inhibitors for patients with hormone receptor (HR)-positive HER2-negative metastatic breast cancer (BC) presenting with visceral crisis or life-threatening conditions represent a challenge for daily clinical practice. Indeed, the peculiarity of this clinical presentation (signs and symptoms of rapidly progressive disease) does not allow to include such patients in a trial aiming for drug approval. On the basis of the scientific evidence available so far, chemotherapy represents the standard of care according to guidelines, on the basis of the more rapid activity in comparison with ET alone. Besides, the combination of ET and CDK4/6 inhibitors have demonstrated in clinical trials to have clinically impactful activity in a short time, thus suggesting a potential role in advanced tumors that require rapid response. Herein, we report the clinical history of a young woman with HR-positive HER2-negative metastatic BC and a pancytopenia due to carcinomatosis of the bone marrow receiving letrozole and leuprorelin plus the CDK4/6 inhibitor palbociclib, who significantly derived clinical benefit from treatment. Considering that these peculiar cases are excluded from clinical trials, the estimation of the magnitude of the benefit of the newer ET combination may potentially represent a practical question for large case series and real-world studies. Frontiers Media S.A. 2021-10-07 /pmc/articles/PMC8529000/ /pubmed/34692469 http://dx.doi.org/10.3389/fonc.2021.651723 Text en Copyright © 2021 Garufi, Carbognin, Orlandi, Palazzo, Tortora and Bria https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Garufi, Giovanna Carbognin, Luisa Orlandi, Armando Palazzo, Antonella Tortora, Giampaolo Bria, Emilio The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature |
title | The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature |
title_full | The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature |
title_fullStr | The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature |
title_full_unstemmed | The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature |
title_short | The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature |
title_sort | therapeutic challenge of disseminated bone marrow metastasis from hr-positive her2-negative breast cancer: case report and review of the literature |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529000/ https://www.ncbi.nlm.nih.gov/pubmed/34692469 http://dx.doi.org/10.3389/fonc.2021.651723 |
work_keys_str_mv | AT garufigiovanna thetherapeuticchallengeofdisseminatedbonemarrowmetastasisfromhrpositiveher2negativebreastcancercasereportandreviewoftheliterature AT carbogninluisa thetherapeuticchallengeofdisseminatedbonemarrowmetastasisfromhrpositiveher2negativebreastcancercasereportandreviewoftheliterature AT orlandiarmando thetherapeuticchallengeofdisseminatedbonemarrowmetastasisfromhrpositiveher2negativebreastcancercasereportandreviewoftheliterature AT palazzoantonella thetherapeuticchallengeofdisseminatedbonemarrowmetastasisfromhrpositiveher2negativebreastcancercasereportandreviewoftheliterature AT tortoragiampaolo thetherapeuticchallengeofdisseminatedbonemarrowmetastasisfromhrpositiveher2negativebreastcancercasereportandreviewoftheliterature AT briaemilio thetherapeuticchallengeofdisseminatedbonemarrowmetastasisfromhrpositiveher2negativebreastcancercasereportandreviewoftheliterature AT garufigiovanna therapeuticchallengeofdisseminatedbonemarrowmetastasisfromhrpositiveher2negativebreastcancercasereportandreviewoftheliterature AT carbogninluisa therapeuticchallengeofdisseminatedbonemarrowmetastasisfromhrpositiveher2negativebreastcancercasereportandreviewoftheliterature AT orlandiarmando therapeuticchallengeofdisseminatedbonemarrowmetastasisfromhrpositiveher2negativebreastcancercasereportandreviewoftheliterature AT palazzoantonella therapeuticchallengeofdisseminatedbonemarrowmetastasisfromhrpositiveher2negativebreastcancercasereportandreviewoftheliterature AT tortoragiampaolo therapeuticchallengeofdisseminatedbonemarrowmetastasisfromhrpositiveher2negativebreastcancercasereportandreviewoftheliterature AT briaemilio therapeuticchallengeofdisseminatedbonemarrowmetastasisfromhrpositiveher2negativebreastcancercasereportandreviewoftheliterature |